PublicationsSearch by:Platform- DolaLock (16)
- Dolaflexin (14)
- Dolasynthen (5)
- Immunosynthen (7)
- Other (3)
Program- XMT-1536 (10)
- XMT-1522 (4)
- XMT-2056 (2)
Year- 2021
- 2020
- 2019
- 2018
- 2017
- 2016
- 2015
- 2014
- 2013
Platform
- DolaLock (16)
- Dolaflexin (14)
- Dolasynthen (5)
- Immunosynthen (7)
- Other (3)
Program
- XMT-1536 (10)
- XMT-1522 (4)
- XMT-2056 (2)
Year
- 2021
- 2020
- 2019
- 2018
- 2017
- 2016
- 2015
- 2014
- 2013
XMT-1660, a B7-H4-Targeted Dolasynthen Antibody-Drug Conjugate for the Treatment of Breast Cancer
American Association for Cancer Research (AACR)
April, 2021
XMT-2056, a well-tolerated, Immunosynthen-based STING-agonist antibody-drug conjugate which induces anti-tumor immune activity
American Association for Cancer Research (AACR)
April, 2021
Tumor cell-intrinsic STING pathway activation leads to robust induction of Type III Interferons and contributes to the anti-tumor activity elicited by STING agonism
American Association for Cancer Research (AACR)
April, 2021
Dolaflexin: A Novel Antibody-Drug Conjugate Platform Featuring High Drug Loading and a Controlled Bystander Effect
Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research (AACR)
March, 2021
The Dolaflexin-based antibody-drug conjugate XMT-1536 targets the solid tumor lineage antigen SLC34A2/NaPi2b
Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research (AACR)
March, 2021
Tumor cell-intrinsic STING pathway is activated in the presence of cues from immune cells and contributes to the anti-tumor activity of tumor cell-targeted STING agonist antibody-drug conjugates
Society for Immunotherapy of Cancer (SITC)
November, 2020
Safety and Efficacy of XMT-1536 in Ovarian Cancer: A Subgroup Analysis from the Phase 1 Expansion Study of XMT-1536, a NaPi2b Antibody-Drug Conjugate
European Society of Medical Oncology (ESMO)
September, 2020
Tumor Targeting of a STING Agonist by Means of an Antibody-Drug Conjugate Induces Potent Anti-Tumor Immune Responses
Innate Immunity Stimulating Therapies Summit
July, 2020
Systemic Administration of STING Agonist Antibody-Drug Conjugates Elicit Potent Anti-Tumor Immune Responses with Minimal Induction of Circulating Cytokines
American Association for Cancer Research (AACR)
June, 2020
XMT-1592, a Site-Specific Dolasynthen-Based NaPi2b-Targeted Antibody-Drug Conjugate for the Treatment of Ovarian Cancer and Lung Adenocarcinoma
American Association for Cancer Research (AACR)
June, 2020
Phase 1 expansion study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC): Preliminary efficacy, safety, and biomarker results in patients with previously treated metastatic ovarian cancer (OC) or non-small cell lung cancer (NSCLC)
American Society of Clinical Oncology (ASCO)
May, 2020
A Phase 1 study of XMT-1536 in patients with solid tumors likely to express NaPi2b: A summary of dose escalation
SGO 2020 Annual Meeting on Women’s Cancer
May, 2020
Tumor targeting of a STING agonist with an antibody drug conjugate elicits potent anti-tumor immune responses
Society for Immunotherapy of Cancer (SITC)
November, 2019
NaPi2b Expression in a Large Surgical Non-Small Cell Lung Cancer (NSCLC) Cohort
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October, 2019
Simultaneous quantification of total antibody and antibody-conjugated drug for XMT-1522 in human plasma using immunocapture-liquid chromatography/mass spectrometry.
Journal of Pharmaceutical and Biomedical Analysis, Volume 174, 10 September 2019, Pages 441-449
September, 2019
Phase 1 dose escalation study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC), in patients (pts) with solid tumors likely to express NaPi2b
American Society of Clinical Oncology (ASCO)
June, 2019
Dolasynthen: A Novel, Homogeneous Auristatin F Hydroxypropyl Amide Antibody-Drug Conjugate Platform
American Association for Cancer Research (AACR)
April, 2019
An Antibody-Drug Conjugate Carrying a Microtubule Inhibitor and a DNA Alkylator Exerts Both Mechanisms of Action on Tumor Cells
American Association for Cancer Research (AACR)
March, 2019
Target Expression/Efficacy Relationship of XMT-1522, a HER2-targeting Antibody Drug Conjugate (ADC), in an Unselected Series of Non-small Cell Lung Cancer (NSCLC) Primary Human Carcinoma Xenografts.
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
November, 2018
Discovery of the novel, homogeneous payload platform Dolasynthen for Antibody-Drug Conjugates
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
November, 2018
Indole-Biaryl Pyrrolobenzodiazepines (I-BiPs): A Potent and Well-tolerated Class of DNA Mono-alkylating Payload for Antibody-Drug Conjugates (ADCs)
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
November, 2018
MERS67 is a Novel anti-NaPi2b Antibody and Demonstrates Differential Expression Patterns in Lung Cancer Histologic Subtypes
International Association for the Study of Lung Cancer (IASLC)
September, 2018
Phase 1 dose escalation of XMT-1522, a novel HER2-targeting antibody-drug conjugate (ADC), in patients with HER2-expressing breast, lung and gastric cancer
American Society of Clinical Oncology (ASCO)
June, 2018
Unique Pharmacological Properties of Dolaflexin-Based ADCs – A Controlled Bystander Effect
American Association for Cancer Research (AACR)
April, 2018
Synergy of an anti-HER2 ADC TAK-522 (XMT-1522) in combination with anti-PD1 mAb in a syngeneic breast cancer model expressing human HER2
American Association for Cancer Research (AACR)
April, 2018
Relationship of NaPi2b expression and efficacy of XMT-1536, a NaPi2b targeting antibody drug conjugate (ADC), in an unselected panel of human primary ovarian mouse xenograft models
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October, 2017
A phase Ib, first-in-human, dose escalation and expansion study of XMT-1522, a novel antibody-drug conjugate (ADC) directed against HER2, in patients with advanced breast cancer and other advanced tumors expressing HER2
June, 2017
Non-clinical pharmacokinetics of XMT-1522, a HER2 targeting auristatin-based antibody drug conjugate
April, 2017
Combination of anti-HER2 ADC XMT-1522 and checkpoint inhibitor pembrolizumab for treatment of NSCLC in preclinical models
April, 2017
A NaPi2b Antibody-Drug Conjugate Induces Durable Complete Tumor Regressions in Patient-Derived Xenograft Models of NSCLC
December, 2016
Discovery and preclinical development of a highly potent NaPi2b-targeted antibody-drug conjugate (ADC) with significant activity in patient-derived non-small cell lung cancer (NSCLC) xenograft models
April, 2016
Optimization of lead antibody selection for XMT-1522, a novel, highly potent HER2-targeted antibody-drug conjugate (ADC)
April, 2016
XMT-1522 induces tumor regressions in pre-clinical models representing HER2-positive and HER2 low-expressing breast cancer.
December, 2015
A Polymer-Based Antibody–Vinca Drug Conjugate Platform: Characterization and Preclinical Efficacy
June, 2015
A novel, highly potent HER2-targeted antibody-drug conjugate (ADC) for the treatment of low HER2-expressing tumors and combination with trastuzumab-based regimens in HER2-driven tumors
April, 2015
Trastuzumab-Dolaflexin, a Highly Potent Fleximer-Based Antibody-Drug Conjugate, Demonstrates a Favorable Therapeutic Index in Exploratory Toxicology Studies in Multiple Species
April, 2015